SCHEDULE 13G/A: Millennium Management Discloses 2.7% Stake in MacroGenics, Inc.

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has disclosed a beneficial ownership of 2.7% of MacroGenics, Inc.'s common stock, totaling 1,724,250 shares.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively beneficially own 1,724,250 shares of MacroGenics, Inc. common stock.
• This ownership represents 2.7% of the total outstanding common stock of MacroGenics, Inc.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously reported stake.
• The reporting persons share both voting and dispositive power over all the reported shares.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual, compliance-driven filing (Schedule 13G) reporting beneficial ownership. It contains no qualitative information, forward-looking statements, or performance metrics that would indicate a positive or negative sentiment. Therefore, it is neutral.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment firm, Millennium Management, holds a stake in MacroGenics, Inc., a biotechnology company. Such disclosures are routine for large investment funds and provide transparency into their portfolio holdings, which can be of interest to other investors tracking institutional sentiment in the biotechnology sector.

Stakeholder Impact

• Shareholders: Provides transparency on institutional ownership, potentially influencing investor sentiment.
• Investment Professionals: Offers insight into the portfolio holdings of a major investment firm.

Key Dates

Keywords

MacroGenics Inc., Millennium Management LLC, Millennium Group Management LLC, Israel A. Englander, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Biotechnology